Originally published March 2025.
Welcome to Insider deep-dive issue #35.
Also, hello to the 425 life science professionals who joined us last month. If you haven’t already upgraded to a paid subscription to unlock our in-depth analysis issues like this one, you can do so here.
In this month’s analysis, we examine FDA guidance on in-process testing for pharmaceutical manufacturers, analyze the pattern of medical device recalls that defined 2024, and dissect four recent warning letters that reveal persistent vulnerabilities across the global pharmaceutical supply chain.
Download this content to use any way you’d like:
